“CYTK Investors: Urgent Action Needed Before Nov 17 Deadline!”

Introduction and Context

Cytokinetics, Inc. (NASDAQ: CYTK) is a late-stage biopharmaceutical company focused on novel muscle biology drugs for cardiovascular and neuromuscular diseases. Recently, CYTK has come under scrutiny due to regulatory setbacks and consequent shareholder legal action. In fact, investors who bought CYTK between Dec 27, 2023 and May 6, 2025 and suffered losses are being reminded of a November 17, 2025 deadline to seek lead plaintiff status in a securities class action (^[1]). This “urgent action” reflects allegations that Cytokinetics misled investors about its flagship drug’s FDA approval timeline (^[1]). With that backdrop, it’s timely to review CYTK’s fundamentals – from dividend policy and leverage to valuation and risks – to inform investors’ decisions before the deadline.

Dividend Policy & Yield

Cytokinetics does not pay any dividend, nor has it ever paid one. The company has stated it has “never paid dividends on our capital stock” and does not anticipate paying cash dividends in the foreseeable future (^[2]). This is typical for development-stage biotech firms, which reinvest any available funds into R&D rather than shareholder payouts. Consequently, CYTK’s dividend yield is 0%, and metrics like FFO or AFFO (commonly used for REITs and income stocks) are not applicable here. Investors focused on income or cash yield will not find it in CYTK – any potential return hinges entirely on stock price appreciation driven by the company’s future successes (or failures), not on dividend distributions.

Leverage and Debt Maturities

Leverage has been a key part of Cytokinetics’ financing strategy. As of December 31, 2023, the company had about $617.5 million in total debt on its balance sheet (^[3]). This debt load is composed of two main pieces: a Royalty Pharma term loan facility and several issues of convertible senior notes (^[3]).

– Royalty Pharma Loan: In early 2022 Cytokinetics entered a funding deal with Royalty Pharma, securing up to $300 million in loan capital to support its drug launches (^[4]). The initial tranche was $50 million, with four additional $50 million tranches contingent on milestones for its drugs omecamtiv mecarbil and aficamten (^[4]). Notably, this loan is structured unconventionally: each draw has a 6-quarter interest-free period, then is repaid over 34 quarters at 1.9× the amount drawn (^[4]) (^[4]). This effectively builds in a significant return for the lender (nearly 90% payback over ~8.5 years). As of 2023, only the initial tranche appears to have been drawn (net carrying ~$58 million) (^[3]) (^[3]). Repayments began in mid-2023, and Cytokinetics will owe Royalty Pharma 1.9× any drawn amount via quarterly installments extending into 2030+ (^[4]). This loan is substantial leverage but repayment is tied to long-term success – if the drugs falter, Cytokinetics still owes the fixed payback, pressuring future cash flows.

– 2026 Convertible Notes: In late 2019, the company issued $138 million of 4.0% convertible senior notes due November 15, 2026 (^[2]). These notes carry a conversion price of ~$10.55/share (94.78 shares per $1,000 note) (^[2]), which is deep in the money with CYTK stock now trading around $50-$60. In 2022 Cytokinetics repurchased the majority of this series – about $116.9 million principal – using cash and equity (8.07 million shares) from a new financing (^[5]) (^[5]). As of the end of 2023, only $21.1 million principal of the 2026 notes remain outstanding (^[3]). The remainder will likely be either converted by holders or redeemed by the company before the 2026 maturity, given the stock’s high price (the company can call these notes since CYTK shares have long exceeded 130% of the conversion price) (^[3]). In effect, the 2026 debt is almost off the books, either turning into about 2 million new shares or a small cash outlay of $21M.

– 2027 Convertible Notes: In July 2022, Cytokinetics issued $540 million of 3.50% convertible senior notes due July 1, 2027 (^[3]). The initial conversion price was ~$51.08/share (a 30% premium at issuance) (^[5]). These notes provided a massive cash infusion for R&D and also funded the retirement of most 2026 notes as noted above. However, facing a high coupon and a nearer maturity, Cytokinetics moved in late 2025 to refinance a large portion of this debt. In September 2025, the company announced an upsized $650 million offering of new convertible notes due 2031 at just 1.75% interest (^[6]). The proceeds were used to retire about $399.5 million of the 2027 notes (essentially swapping those holders into the new 2031 notes) (^[6]). As a result, approximately $140 million of the 2027 notes remain outstanding on the books, while the bulk was pushed out to 2031. The new 2031 notes carry an initial conversion price of ~$68.42 (a 37.5% premium to CYTK’s Sep 2025 share price) (^[6]) (^[6]), and cannot be converted by holders until close to maturity except under certain conditions (^[6]). Cytokinetics achieved a much lower coupon (1.75%) and higher conversion threshold with this refinancing (^[6]), trading some future dilution for immediate interest expense relief. In summary, the near-term maturity overhang is reduced – only ~$140M comes due in 2027 now – but total debt rose by the net $250M extra raised. The 2031 notes ($650M due) become the big long-term liability, although if CYTK’s future is bright, those too could eventually convert to equity at ~$68/share.

Overall, Cytokinetics’ leverage is significant but of long tenor. As of Dec 2023, net carrying debt was about $607 million (term loan + 2026 & 2027 notes) (^[3]), against $655 million in cash and securities on hand (^[3]). After the 2025 refinancing and recent deals, the debt mix is now skewed to low-coupon convertible notes due 2027 and 2031. These instruments defer any cash principal outlay for years, essentially financing the company’s R&D pipeline at the cost of future dilution. Investors should monitor these maturities: the small 2026 notes will likely convert (adding shares), the residual 2027 notes might convert or need repayment by mid-2027, and the large 2031 notes loom further out. The Royalty Pharma loan adds another layer of fixed obligations (with payments already underway). While none of the debt is due immediately, by 2027–2031 Cytokinetics will either need commercial success or additional refinancing to meet these commitments.

Cash Flow and Coverage

Given its stage, Cytokinetics operates at a substantial net loss and cash burn, which makes traditional coverage ratios weak. In 2023, the company’s net loss was $526 million (^[3]), and operating cash outflow was about $414 million for the year (^[3]). These losses have been widening as late-stage trials and pre-commercial activities ramp up (net loss was $389M in 2022 and $215M in 2021) (^[3]).

With negative EBITDA and no meaningful earnings, Cytokinetics’ interest coverage (EBIT/interest) is effectively non-existent – the company currently cannot cover interest costs out of operating profit. However, its interest expenses remain relatively modest compared to the cash burn. Thanks to low coupons on the convertibles and the Royalty Pharma deal’s structure, CYTK’s cash interest paid was only ~$10.3 million in 2023 (down from $15.2M in 2022) (^[3]). The refinanced 1.75% notes will further cut the yearly interest expense. In other words, debt service is not the primary drain on cash – R&D and operating costs are. For now, the company is funding these costs from its cash reserves and periodic financing activities (debt or equity issuance).

Liquidity: As noted, Cytokinetics ended 2023 with $655.3 million in cash, equivalents and investments (^[3]). This war chest was bolstered by financing moves like a $164M ATM equity offering in 2023 (5 million shares issued) (^[3]), and will be further boosted by the net ~$250M raised in late 2025 from the convertible issuance. Management believed this cash was sufficient for at least 12 months of operations beyond early 2024 (^[3]). In practice, the cash runway likely extends into 2025–2026, depending on spending. It’s worth noting Cytokinetics also received a €50 million upfront payment (~$53M) from Bayer in late 2024 for licensing aficamten in Japan (^[7]) (with potential milestone payments to come), which adds to near-term liquidity.

Nonetheless, if the company’s flagship drug gets delayed or fails approval, additional funding would be needed. CYTK has proven adept at tapping capital markets (convertible notes, ATM stock sales, partnerships), but that can dilute existing shareholders or add debt. On a positive note, the convertible structure means much of the debt could convert to equity if the company succeeds (reducing cash repayment burdens). On the negative side, if the business struggles and the share price falls, those notes stay as debt, and coverage could become a concern by 2027. For now, interest obligations are well-covered by cash on hand, but operational cash burn is the bigger issue – Cytokinetics must either start generating revenue in the next couple of years or continue raising capital to fund its operations.

Valuation and Comparables

Traditional valuation metrics paint an unusual picture for CYTK, given its minimal revenues and large future potential. With the stock around the mid-$50s recently, Cytokinetics’ market capitalization is roughly $7–8 billion (^[8]). Yet the company’s trailing 12-month revenue is only on the order of $18 million (^[8]) (essentially derived from R&D collaborations or milestone payments). This implies an astronomical price-to-sales ratio (P/S) in the hundreds, underscoring that investors are valuing Cytokinetics for its pipeline and future prospects, not current earnings. The firm’s book value is negative (accumulated deficit over $2.1B has wiped out accounting equity (^[3]) (^[3])), so metrics like P/B or P/E are not meaningful – the stock effectively trades on intangible asset value (expected drug approvals and sales). In sum, by conventional metrics the stock looks extremely expensive, but this is typical for a late-stage biotech with a potentially blockbuster drug nearing the market.

A more relevant way to gauge valuation is by comparison to peers and precedent deals in the biotech space: – Comparable Transactions: An instructive example is Bristol Myers Squibb’s acquisition of MyoKardia in 2020 for $13.1 billion (^[9]). MyoKardia’s prize asset was mavacamten (now marketed as Camzyos), a first-in-class drug for obstructive hypertrophic cardiomyopathy (oHCM) – essentially the same indication Cytokinetics’ aficamten is targeting (^[9]). BMS’s willingness to pay over $13B (for a company with no approved drugs at the time) highlighted the high expected value of successful HCM therapies. By comparison, CYTK’s ~$7–8B market cap could be seen as reflecting aficamten’s potential, albeit tempered by remaining risks. Investors are effectively pricing Cytokinetics at roughly half the MyoKardia takeout value, possibly due to (a) the presence of an entrenched competitor (Camzyos is already on the market), and (b) the hiccups Cytokinetics has had in development.

– Peer Performance: Bristol Myers’ Camzyos (mavacamten) was approved in 2022 and is now CYTK’s direct competitor in obstructive HCM. Camzyos sales are growing but still modest as the market builds – BMS reported the drug more than doubled its sales year-over-year, reaching tens of millions per quarter by 2024 (^[10]). Analysts project peak annual sales for Camzyos in the low-to-mid single-digit billions of dollars if the HCM market is fully penetrated. Cytokinetics’ aficamten could potentially share (or grow) this market, but coming second-to-market often entails capturing a smaller share or needing superior data. The current valuation implies investors expect aficamten to be a commercial success, but perhaps not to completely unseat BMS’s offering.

– Partnerships and Royalties: The recent Bayer deal provides an external validation datapoint for aficamten’s value. In November 2024, Bayer paid €50M upfront and up to €90M in development milestones for Japanese rights to aficamten, plus up to €490M in sales milestones contingent on success (^[7]) (^[7]). While structured heavily toward back-end milestones, this deal suggests a total potential value of ~€630M ($670M) for one major market’s rights. Extrapolated, global rights for aficamten (if the drug fulfills its promise) could be worth several times that amount. Cytokinetics retained U.S. and other territories, meaning it could either commercialize on its own or strike similar partnerships in Europe or elsewhere. These partnerships might not immediately close CYTK’s valuation gap, but they could de-risk the path to revenue and bring in non-dilutive capital (the Bayer upfront helps offset cash burn).

In conclusion, Cytokinetics’ valuation is highly speculative and contingent. The stock’s ~$7-8B value reflects optimism that aficamten (and possibly other pipeline assets) will generate significant future cash flows, either through direct sales or via an acquisition by Big Pharma. Investors should note that any failure or delay in the pipeline could cause sharp valuation compression, while conversely a major success (e.g. FDA approval and strong launch of aficamten, or a lucrative buyout offer) could justify or even exceed the current market price. This binary, risk/reward profile is common in biotech – CYTK is trading more on clinical trial data and FDA decisions than on financial ratios.

Risks and Red Flags

Investing in Cytokinetics entails substantial risks, and recent events have raised a few red flags that investors must regard with caution:

– Regulatory Setback (Aficamten NDA Delay): Cytokinetics’ lead drug aficamten is under FDA review for obstructive hypertrophic cardiomyopathy. The company initially guided that it expected FDA approval in H2 2025 (with a PDUFA action date of Sept 26, 2025). However, in May 2025 it was revealed that Cytokinetics had not included a Risk Evaluation and Mitigation Strategy (REMS) in its NDA filing despite prior discussions with the FDA (^[1]) (^[1]). The FDA, concerned about safety monitoring, extended the review by three months to December 26, 2025 to allow assessment of risk mitigation plans (^[11]). This delay was a negative surprise that hit the stock and is at the core of the shareholder lawsuit. The red flag is that management’s communication was overly optimistic – they “failed to disclose material risks” about the approval timeline (^[1]). Needing a REMS suggests safety issues (likely risk of excessive cardiac suppression) that could not only delay approval but also, if approved, restrict aficamten’s use (REMS programs can limit distribution or require ongoing patient monitoring). The takeaway risk: Regulatory outcomes are uncertain, and even a delayed approval or label restrictions can significantly impact the drug’s commercial prospects. Investors must be prepared for the possibility that aficamten’s FDA decision (due late Dec 2025) could be further delayed or even negative, especially in light of this REMS issue.

– Shareholder Litigation and Governance Concerns: The aforementioned surprise has led to at least one class-action investigation. A prominent securities law firm (Faruqi & Faruqi) alleges that Cytokinetics misled investors regarding aficamten’s approval timeline and risk management, and is encouraging shareholders to join a lawsuit (^[1]) (^[1]). The deadline of Nov 17, 2025 to seek lead plaintiff status highlights the urgency for affected investors (^[1]). While such lawsuits are not uncommon after biotech stock drops, they flag potential governance issues – either poor judgment or transparency by management. If the suit proceeds, it could result in legal costs or settlements for CYTK (though likely not material compared to its market cap), and it underscores a trust deficit between management and some shareholders. At minimum, management will need to improve its risk disclosures going forward. This is a risk factor for investors as it could distract leadership and marginally constrain cash (if a settlement arises). More broadly, it’s a signal that Cytokinetics’ credibility suffered a blow due to how it handled the FDA submission.

– Pipeline Dependency and Failures: Cytokinetics is essentially a one-product story at this point, which heightens risk. Its pipeline beyond aficamten has seen setbacks. Notably, the company’s previous lead program, omecamtiv mecarbil for heart failure, received a Complete Response Letter (CRL) from the FDA in Feb 2023 – regulators concluded that the Phase 3 trial (GALACTIC-HF) did not provide sufficient evidence of effectiveness for approval (^[12]). An FDA advisory committee had voted against omecamtiv’s risk/benefit in late 2022, leading to this rejection. Cytokinetics would need additional trials to rescue omecamtiv, but it’s unclear if they will invest further; effectively, years of work and money on omecamtiv have not yielded an approval. Another major setback came in early 2023 when the company halted its Phase 3 COURAGE-ALS trial of reldesemtiv (a skeletal muscle activator for ALS) due to futility – an interim analysis showed no efficacy benefit (^[13]). That program was discontinued, representing a lost opportunity in neuromuscular disease. These failures mean that aficamten is carrying nearly all of the company’s value now. This is a classic “all eggs in one basket” scenario: if aficamten fails to secure approval or to achieve commercial success, Cytokinetics has no approved products to fall back on. Even if smaller earlier-stage programs (like CK-136 or CK-586 for heart failure and CK-089 for muscle diseases) are in the works (^[14]), (^[14]) those are years behind and uncertain. The risk is high because Cytokinetics’ future hinges on one drug, and drug development is fraught with uncertainty.

– Commercialization and Competition: Assuming aficamten does get approved, commercial risk becomes key. Cytokinetics has never marketed a drug on its own. Launching a cardiovascular drug will require building or outsourcing a sales force, educating clinicians (cardiologists), and possibly managing a REMS program – all costly endeavors. The company has been preparing (it signaled investments in commercial readiness in its financing disclosures) (^[5]), but execution risk is significant for a first-time commercial venture. Furthermore, competition is already in the market: Bristol Myers Squibb’s Camzyos (mavacamten) is approved for the same indication (oHCM). BMS, with its large resources and existing cardiology franchise, has a big head start. If Camzyos becomes entrenched as standard-of-care, aficamten (as the second entrant) will need to differentiate itself. Cytokinetics argues aficamten might have a dosing advantage or other benefits, but that remains to be proven in real-world use. Meanwhile, physician caution could be higher after one drug in this class already mandated a REMS (Camzyos in the U.S. requires careful echo monitoring due to risk of over-suppressing heart function). If aficamten ends up with similar safety precautions, doctors might stick to the devil they know (Camzyos). On the other hand, any misstep by BMS can be an opportunity (indeed, BMS recently reported that mavacamten failed to meet endpoints in a trial for non-obstructive HCM (^[15]), leaving an unmet need in that population which aficamten is also pursuing). In short, Cytokinetics faces competition risk from a formidable rival and must execute a superior commercial strategy to capture market share. Failure to do so would jeopardize the lofty sales expectations embedded in its valuation.

– Financial & Dilution Risk: As detailed earlier, Cytokinetics will likely continue to operate at a loss into 2025 and 2026, even if aficamten launches (since revenues ramp gradually). There is a risk of further dilution or debt if timelines slip or cash burn stays high. The company’s share count has steadily climbed (about 101.6 million shares at end of 2023, up from ~84.8M at end of 2021) (^[3]) due to stock offerings and convertible note conversions. Investors should expect this trend to continue: for example, conversion of the remaining 2026/2027 notes could add roughly 2–3% more shares, and stock-based compensation (CYTK had $72M in non-cash comp expense in 2023) (^[3]) will also dilute holders over time. If aficamten’s approval is delayed beyond late 2025, management might feel pressure to raise equity or draw more Royalty Pharma debt to extend runway, especially with a $140M principal payment hanging in 2027. Such actions could come at unfavorable terms if the stock is depressed. High leverage plus negative earnings also makes CYTK’s stock more volatile – any hint of credit tightening or risk-off sentiment in markets can punish heavily indebted, cash-burning companies.

– Other Red Flags: One red flag to note is negative tangible equity – by GAAP measures, Cytokinetics’ liabilities exceeded its assets by roughly $386 million at the end of 2023 (^[3]). While this is largely due to accounting for convertible notes and accumulated losses (and biotech investors often ignore book value), it underscores that the company is completely dependent on future success to justify its financing structure. Additionally, insiders and large shareholders could influence stock movements (e.g., Royalty Pharma also bought some equity in Cytokinetics as part of deals, and RTW Investments has been a significant backer (^[16])). Any shifts in their stance might impact sentiment. Finally, macro risks – such as rising interest rates, which increase the cost of capital, or changes in healthcare policy – can weigh on all biotechs, Cytokinetics included.

In sum, Cytokinetics is a high-risk, high-reward story. The key red flags include management missteps (as seen with the NDA delay), one-shot pipeline reliance, tough competition, and the need for continuous external funding. Investors should carefully weigh these risks, especially ahead of the Nov 17 class-action deadline if they have experienced losses – it’s a reminder that things have not gone smoothly of late.

Open Questions for Investors

Given the uncertain landscape, several open questions remain that CYTK investors should keep in mind going forward:

– Will aficamten secure FDA approval on the new PDUFA date? The FDA’s decision (expected by Dec 26, 2025) is the single most critical catalyst. Approval is widely anticipated since the Phase 3 trial was positive, but after the REMS-related delay nothing is guaranteed. If approved, will the label have onerous requirements (REMS, black-box warnings, usage limited to certain patient subgroups)? Any surprises in the approval (or a worst-case rejection) would drastically move the stock. This uncertainty will overhang the shares until resolved.

– What will be the commercial game plan (and outcome) for aficamten? Can Cytokinetics, as a first-time commercializer, successfully launch this drug on its own in 2026? Or will it seek a commercial partner or even be acquired by a larger pharmaceutical company? Notably, the company has already partnered Bayer in Japan (^[7]), hinting it may prefer to out-license in some regions while focusing on the U.S. market itself. An open question is whether Cytokinetics might strike a partnership for Europe (as Bayer did with another HCM drug, acoramidis) or if a Big Pharma might attempt to acquire Cytokinetics outright. The MyoKardia precedent (BMS paying $13B for a similar asset) suggests big players are willing to pay if the drug profile is strong (^[9]). For now, management seems intent on U.S. commercialization, but investors should watch for any strategic shifts post-approval.

– How will aficamten compete against BMS’s Camzyos? This is both a risk and an opportunity. Can Cytokinetics differentiate its drug’s profile (e.g., dosing regimen, fewer drug interactions, price advantage) to gain market share? It’s possible the HCM market could expand enough to accommodate two therapies, but if competition turns into a zero-sum game for a niche population, sales expectations might need to be tempered. Also, will aficamten succeed in non-obstructive HCM where Camzyos just failed (^[15])? Cytokinetics is conducting trials in that broader patient group – positive data there could open a new market and give aficamten an edge if Camzyos cannot obtain that indication. The answers will unfold in upcoming trial readouts and post-marketing studies.

– Can Cytokinetics rejuvenate its pipeline beyond aficamten? Once aficamten’s fate is decided, attention will turn to the next acts. The company’s pipeline in 2024–25 includes earlier-stage programs: CK-136 (a cardiac myosin inhibitor for heart failure with preserved EF), CK-586 (a different mechanism for heart failure), and CK-089 (a skeletal muscle activator for a form of muscular dystrophy) (^[14]). These are still in Phase 1 or pre-clinical stages. An open question is whether Cytokinetics will advance these on its own or seek partners (to share cost and risk). Given the heavy investment needed, the company might prioritize aficamten’s commercialization in the near term, but long-term growth will require new successes. Investors should watch for any new collaborations or trial initiations that could add value beyond the HCM franchise. Another question: will omecamtiv mecarbil get another chance? The company hinted at discussing next steps with FDA despite the CRL (^[12]). It’s uncertain if a narrower trial (perhaps in a severe heart failure subset) could resurrect that drug, or if it’s effectively shelved. The strategy on omecamtiv remains an open item.

– How will the class-action and investor sentiment play out? In the short term, November 17, 2025 marks the investor deadline to join the lawsuit (^[1]). The outcome of this legal matter (be it dismissal, settlement, or protracted litigation) is unclear. While such suits typically take time and may have limited financial impact on the company, they could influence management behavior and investor sentiment. It’s an open question whether any internal changes (e.g., enhanced compliance processes or even personnel changes) will result from this scrutiny. Investors will want to see management acknowledge lessons learned and improve transparency moving forward.

– Does the current valuation adequately price in risks? This is a more subjective question, but vital. CYTK’s valuation anticipates a successful launch and significant revenue by late this decade. Any deviance – slower uptake, additional trials, greater expenses – could mean the stock is ahead of itself. Conversely, if everything goes right (FDA approval, strong uptake, perhaps eventual takeover interest from Big Pharma), current prices might in hindsight look cheap. The range of outcomes is wide. Investors must ask themselves if they are comfortable with the risk/reward at play. With the stock elevated by hope, there is little margin for error – a true binary situation is unfolding in the next 6–12 months.

In summary, Cytokinetics presents pivotal questions that will resolve in the coming quarters. The Nov 17 legal deadline brings immediacy for those seeking recourse for past losses, but for current and prospective shareholders, the bigger questions revolve around what happens by the end of 2025 and beyond. Aficamten’s approval and launch are the defining events on the horizon. Clarity on those fronts will answer many of these open questions – and likely determine whether CYTK proves to be a lucrative investment or a cautionary tale. Until then, investors should stay vigilant and informed about each development, weighing the company’s significant potential against its very real risks.

Sources: The information in this report is compiled from Cytokinetics’ SEC filings, official press releases, and credible financial news outlets. Key references include the company’s 2023 Annual Report (10-K) for financials and risk factors (^[3]) (^[3]), recent press releases on the FDA review timeline (^[1]) and financing transactions (^[6]), and news reports from Reuters and others regarding partnership deals and industry context (^[7]) (^[9]). These sources are cited inline throughout the report for verification and further reading.

Sources

1. https://ainvest.com/news/cytokinetics-investors-alert-deadline-seek-lead-plaintiff-november-17-2025-2509/
2. https://sec.gov/Archives/edgar/data/1061983/000156459022007218/cytk-10k_20211231.htm
3. https://sec.gov/Archives/edgar/data/1061983/000095017024022256/cytk-20231231.htm
4. https://royaltypharma.com/news/royalty-pharma-and-cytokinetics-announce-funding-agreements-totaling-up-to-450-million/
5. https://globenewswire.com/news-release/2022/07/01/2472665/35409/en/Cytokinetics-Announces-Pricing-of-450-Million-Convertible-Senior-Notes-Offering.html
6. https://ir.cytokinetics.com/press-releases/press-release-details/2025/Cytokinetics-Announces-Pricing-of-Upsized-650-0-Million-Convertible-Senior-Notes-Offering-Refinances-a-Portion-of-2027-Convertible-Notes/default.aspx
7. https://reuters.com/business/healthcare-pharmaceuticals/bayer-acquires-rights-cytokinetics-heart-drug-japan-2024-11-19/
8. https://macrotrends.net/stocks/charts/CYTK/cytokinetics/dividend-yield-history
9. https://axios.com/2020/10/05/bristol-myers-squibb-myokardia
10. https://reuters.com/business/healthcare-pharmaceuticals/bristol-myers-q3-earnings-beat-expectations-helped-by-sales-older-drugs-2024-10-31/
11. https://ir.cytokinetics.com/press-releases/press-release-details/2025/Cytokinetics-Announces-New-PDUFA-Date-for-Aficamten-in-Obstructive-Hypertrophic-Cardiomyopathy-05-01-2025/default.aspx
12. https://ir.cytokinetics.com/press-releases/press-release-details/2023/Cytokinetics-Receives-Complete-Response-Letter-From-FDA-for-New-Drug-Application-for-Omecamtiv-Mecarbil-02-28-2023/default.aspx
13. https://tricals.org/news/courage-als-trial-discontinued-due-to-disappointing-results?nav_context=0
14. https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-announces-new-pdufa-date-aficamten-obstructive
15. https://reuters.com/business/healthcare-pharmaceuticals/bristol-myers-heart-disease-drug-fails-meet-main-goals-late-stage-study-2025-04-14/
16. https://ir.cytokinetics.com/press-releases/press-release-details/2021/Cytokinetics-and-JI-XING-Announce-Expansion-of-Collaboration-to-Include-Licensing-of-Omecamtiv-Mecarbil-in-China-RTW-to-Add-to-Its-Investment-in-Cytokinetics-12-20-2021/default.aspx

For informational purposes only; not investment advice.